Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Nature Reviews Clinical Oncology – Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Related Articles
Classical Hematology Advancement Mentorship Program (CHAMP) – Hematology.org
Classical Hematology Advancement Mentorship Program (CHAMP)
Welcome! You are invited to join a webinar: Skin VJSessions: Therapeutic Advances in PD-1 Refractory Skin Cancer. After registering, you will receive a confirmation email about joining the webinar.
Therapeutic options for PD-1 refractory skin cancer 3 Jan – 6PM BST | 1PM EDT | 10AM PDT Allison Betof Warner, Omid Hamid, Inderjit Mehmi…
Elections – Society of Surgical Oncology
2025 Society Elections Nominate your peers or submit your self-nomination for open leadership positions within the SSO! All nominations must be received by 4:30 pm…
Odronextamab Demonstrates Safety in Treating DLBCL Population
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma
Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.
Coffee and tea consumption and the risk of head and neck cancer: An updated pooled analysis in the International Head and Neck Cancer Epidemiology Consortium
A pooled analysis of 9548 HNC cases and 15,783 controls from the International Head and Neck Cancer Epidemiology consortium was conducted to assess the association…
Editorial Board Members needed for Colorectal Cancer
Colorectal Cancer provides a concise, readable overview of current and future management options in a fast-moving field, ideal for the busy clinician or healthcare professional.…
Implementing Resource-Stratified Guidelines in LMICs
This Viewpoint discusses the importance of formulating more stable local treatment guidelines because international guidelines and even resource-stratified guidelines may not be as applicable in…
29th Annual Acute Leukemia Forum 2025 | La Jolla, California
Register now and explore groundbreaking advancements in acute leukemia and myelodysplasia treatment at ALF 2025. Stay informed with the latest innovations shaping the future of…
Liso-Cel Shows Broad Spectrum Activity in CIBMTR Cohort of Relapsed/Refractory LBCL
Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.